High-dose cyclophosphamide administered after peripheral blood stem cell (PBSC) transplantation can reduce the risk of chronic graft-versus-host disease (GVHD), according to a single-center study of 43 patients. Median age of the patients was 43 years, and 12 (28%) received grafts from related donors and 31 (72%) received grafts from unrelated donors. Cyclophosphamide was given at 50 mg/kg of patient weight per day on days 3 and 4 after transplantation, followed by cyclosporine starting on day 5. The cumulative 1-year incidence of chronic GVHD was 16%, which the authors note is substantially lower than the approximately 35% rate of 1-year chronic GVHD reported historically after PBSC transplantation.
Choose a Topic
- All Topics
- ASH 2017
- AML
- MDS
- Lymphomas and CLL
- Older Patient HCT
- Sickle Cell Disease
- Post-Transplant
- GVHD
- Patient Eligibility
- CIBMTR Publications
- Cord Blood
- Pediatric HCT
- ALL
- CML
- Multiple Myeloma
- Neuroblastoma
- Non-Malignant Disorders
- HLA Matching
- Preparative Regimens
- BMT CTN Publications
- Unrelated Donor HCT
- ASH 2018
- ASH 2020
Reduced Risk of Chronic GVHD with Post-Transplant Cyclophosphamide
Apr 2016